Article

The Cost of Pediatric Stroke Acute Care in the United States

Department of Pediatrics, The Ohio State University, Columbus, Ohio, United States
Stroke (Impact Factor: 6.02). 09/2009; 40(8):2820-7. DOI: 10.1161/STROKEAHA.109.548156
Source: PubMed

ABSTRACT The cost of pediatric stroke care has received little attention, but the available data suggest it is expensive. To determine the cost of acute stroke, we analyzed a US national database. Method- We used the Kids' Inpatient Database (KID2003) to determine the hospital-based costs of acute stroke in children ages 3 months to 20 years. Discharges were selected if the first diagnostic position contained an International Classification of Diseases, 9th Revision code pertaining to ischemic or hemorrhagic stroke. We examined the relationship between cost and stroke type by adjusting for variables that predict the cost of adult stroke.
There were 2224 pediatric cases, after statistical weighting, discharged with a diagnosis of hemorrhagic or ischemic stroke in KID2003. The estimated cost of acute pediatric stroke in the United States was $42 million in 2003. For the entire cohort, the mean cost of acute hospital care was $20 927 per discharge. The mean cost for ischemic stroke was $15 003, for intracerebral hemorrhage $24 117, and for subarachnoid hemorrhage $31 653. Stroke diagnosis, length of stay, hospital ownership, rural/urban teaching status, US geographical region, and discharge disposition were significantly associated with cost. Cost remained significantly associated with stroke diagnosis after adjusting for other predictors in the final multivariable regression model.
Pediatric stroke is expensive, and the lifetime cost of care is likely greater for a child than an adult. The cost to the family and the larger society underscore the importance of pediatric stroke treatment and prevention.

Download full-text

Full-text

Available from: Huiyun Xiang, Mar 20, 2015
1 Follower
 · 
219 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stroke is a leading cause of morbidity and mortality. While tissue-type plasminogen activator (tPA) remains the only FDA-approved treatment for ischemic stroke, clinical use of tPA has been constrained to roughly 3% of eligible patients because of the danger of intracranial hemorrhage and a narrow 3 h time window for safe administration. Basic science studies indicate that tPA enhances excitotoxic neuronal cell death. In this review, the beneficial and deleterious effects of tPA in ischemic brain are discussed along with emphasis on development of new approaches toward treatment of patients with acute ischemic stroke. In particular, roles of tPA-induced signaling and a novel delivery system for tPA administration based on tPA coupling to carrier red blood cells will be considered as therapeutic modalities for increasing tPA benefit/risk ratio. The concept of the neurovascular unit will be discussed in the context of dynamic relationships between tPA-induced changes in cerebral hemodynamics and histopathologic outcome of CNS ischemia. Additionally, the role of age will be considered since thrombolytic therapy is being increasingly used in the pediatric population, but there are few basic science studies of CNS injury in pediatric animals.
    Journal of Neurochemistry 04/2010; 113(2):303-12. DOI:10.1111/j.1471-4159.2010.06613.x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Knowledge on disease occurrence in the Swedish equine population is lacking. Secondary data (data not produced primarily for research) including medical information offer potential to investigate disease occurrence in populations without primary data collection. This thesis explored the potential use of two nation-wide secondary equine databases for research on diseases in the Swedish horse population. The data quality in one insurance database and one database from a national equine clinic network was evaluated. For diagnostic information, the agreement in insurance data was 84% whereas the completeness (proportion of problems in the clinical records recorded in the database) and correctness (proportion of recorded disease events in the database truly occurring) of clinic data was 91% and 92%, respectively. Logistic regression showed that agreement/correctness was significantly associated with type of visit (clinic data and veterinary care claims in insurance data), whether diagnostic codes were present in the clinical record and affected system (clinic data). To present disease occurrence in the respective study populations, disease was presented as incidence rates (insurance data) and proportional morbidities (both databases). For insurance data, the most commonly affected system was joints, followed by whole body, skin and digestive system. The most common specific diagnosis was fetlock inflammation. For clinic data 22% of all visits were health visits, and for problems visits, the most commonly affected body system was joints, followed by whole body, respiratory and skeleton system. For both databases, disease occurrence was highly related to demographic factors in the horse population. The data quality in both databases was found adequate for research purposes, with due consideration of variation in data quality among disease problems. Presentation of disease indices from the two databases provided useful information on disease occurrence in horses throughout Sweden. Importantly however, as many factors affect disease, results from other studies are not directly applicable to Sweden. Thus disease statistics need be obtained from the specific population of interest.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although many underlying diseases have been reported in the setting of childhood arterial ischemic stroke, emerging research demonstrates that non-atherosclerotic intracerebral arteriopathies in otherwise healthy children are prevalent. Minor infections may play a role in arteriopathies that have no other apparent underlying cause. Although stroke in childhood differs in many aspects from adult stroke, few systematic studies specific to pediatrics are available to inform stroke management. Treatment trials of pediatric stroke are required to determine the best strategies for acute treatment and secondary stroke prevention. The high cost of pediatric stroke to children, families, and society demands further study of its risk factors, management, and outcomes. This review focuses on the recent findings in childhood arterial ischemic stroke.
    Current Atherosclerosis Reports 07/2010; 12(4):217-24. DOI:10.1007/s11883-010-0113-8